Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL

Bone Marrow Transplantation

Volumn 50, Issue 1, 2015, Pages 20-25

  Sun, Y Q ^a   Wang, J ^a   Jiang, Q ^a   Xu, L P ^a   Liu, D H ^a   Zhang, X H ^a   Liu, K Y ^a   Huang, X J ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOSIDE; ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SEMUSTINE; THYMOCYTE ANTIBODY; VINCRISTINE; HLA ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADOLESCENT; ALLOGRAFT; CLINICAL TRIAL; CONSOLIDATION CHEMOTHERAPY; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE;

ADOLESCENT; ADULT; ALLOGRAFTS; CONSOLIDATION CHEMOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE;

EID: 84920650732     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.195     Document Type: Article

References (24)

1. Hoelzer D, Thiel E, Loffler H, Buchner T, Ganser A, Heil G et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-131.
2. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760-3767.
3. Ottinger HD, Ferencik S, Beelen DW, Lindemann M, Peceny R, Elmaagacli AH et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood 2003; 102: 1131-1137.
4. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065-3073.
5. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15: 4777-4783.
6. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827-1833.
7. Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Shi HX et al. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Chin Med J (Engl) 2011; 124: 246-252.
8. Liu KY, Chen YH, Liu DH, Xu LP, Huang XJ. A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation. Bone Marrow Transplant 2008; 42: 535-539.
9. Zhao XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol 2013; 92: 1111-1119.
10. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256-3262.
11. Paulson K, Szwajcer D, Raymond CB, Seftel MD. The role of hematopoietic cell transplantation in adult ALL: clinical equipoise persists. Leuk Res 2014; 38: 176-179.
12. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
13. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574-3581.
14. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH et al. Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012; 18: 716-721.
15. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978-985.
16. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257-265.
17. Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Rhee Fv F et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 2004; 33: 389-396.
18. Lee S, Chung NG, Cho BS, Eom KS, Kim YJ, Kim HJ et al. Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia. Leukemia 2010; 24: 2110-2119.
19. Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 2013; 121: 339-350.
20. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH et al. Superior graft-versusleukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 2011; 17: 821-830.
21. Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve diseasefree survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol 2012; 5: 29.
22. Wang JZ, Liu KY, Xu LP, Liu DH, Han W, Chen H et al. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLAmismatched/haploidentical hematopoietic stem cell transplantation. Transplant Proc 2011; 43: 1928-1933.
23. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia-new drugs and immunotherapy. Best Pract Res Clin Haematol 2008; 21: 683-690.
24. Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E et al. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study. Acta Haematol 2013; 130: 199-205.